Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Gains from Investment Securities (2017 - 2025)

Protagonist Therapeutics' Gains from Investment Securities history spans 9 years, with the latest figure at $7.7 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 27.04% year-over-year to $7.7 million; the TTM value through Dec 2025 reached $7.7 million, down 27.04%, while the annual FY2025 figure was $7.7 million, 27.04% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $7.7 million at Protagonist Therapeutics, up from $1000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $10.5 million in Q4 2024 and bottomed at -$5000.0 in Q1 2025.
  • The 5-year median for Gains from Investment Securities is $6.8 million (2022), against an average of $5.7 million.
  • The largest annual shift saw Gains from Investment Securities plummeted 79.87% in 2021 before it soared 6062.54% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at $5.9 million in 2021, then grew by 9.35% to $6.4 million in 2022, then grew by 22.99% to $7.9 million in 2023, then soared by 32.68% to $10.5 million in 2024, then fell by 27.04% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Gains from Investment Securities are $7.7 million (Q4 2025), $1000.0 (Q3 2025), and -$5000.0 (Q1 2025).